MiNK Therapeutics Reports Durable Clinical Activity for AgenT-797 iNKT Cell Therapy in Advanced Solid Tumors
核心洞察
MiNK Therapeutics will present late-breaking Phase 1 data showing durable clinical activity of AgenT-797, an allogeneic iNKT cell therapy, in patients with advanced solid tumors at SITC 2025.
AgenT-797 is an off-the-shelf, cryopreserved iNKT cell therapy designed to reprogram the immune system and overcome resistance to conventional immunotherapies.
The updated Phase 1 findings will highlight safety and efficacy results from the ongoing study, with presentation scheduled for November 8, 2025.
MiNK Therapeutics announced that late-breaking data demonstrating durable clinical activity of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in advanced solid tumors will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 7-9, 2025, in National Harbor, Maryland.
The presentation, titled "AgenT-797, an Allogeneic iNKT Cell Therapy, Demonstrates Durable Clinical Activity in Solid Tumors: Updated Phase 1 Findings" (LBA #1344), will highlight updated safety and efficacy results from the company's ongoing Phase 1 study of AgenT-797 in patients with advanced solid tumors.
Novel iNKT Cell Therapy Platform
AgenT-797 is an off-the-shelf iNKT cell therapy designed to reprogram the immune system and overcome resistance to conventional immunotherapies. The therapy represents MiNK's lead candidate from its proprietary iNKT platform, which bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.
The allogeneic approach offers significant advantages as a cryopreserved, off-the-shelf treatment that can be readily deployed without the need for patient-specific manufacturing required by autologous cell therapies.
Broad Therapeutic Applications
Beyond solid tumors, AgenT-797 is currently in clinical trials for graft-versus-host disease (GvHD) and critical pulmonary immune failure, demonstrating the versatility of MiNK's iNKT platform. The company's pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation.
Conference Presentation Details
Dr. Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute (搜索) at SCRI Oncology Partners (搜索), will present the findings on Saturday, November 8th. The poster will be available for viewing during two sessions: 12:15-1:45 p.m. ET and 5:10-6:35 p.m. ET at the Prince George ABC Exhibit Halls, Gaylord National Resort & Convention Center.
Company's Immune Reconstitution Approach
MiNK Therapeutics is pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.